Form 4: United Therapeutics EVP Paul Mahon Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 17, 2025, according to a pre-arranged 10b5-1 trading plan.
Summary
- On April 17, 2025, Paul A. Mahon, the EVP & General Counsel of United Therapeutics Corp (UTHR), exercised stock options for 11,000 shares of common stock at a price of $117.76 per share.
- Following the exercise, Mahon sold a total of 11,000 shares in multiple transactions at weighted average prices ranging from $280.3525 to $284.6887.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on December 24, 2024.
- After these transactions, Mahon directly owns 36,781 shares of United Therapeutics common stock and 26,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions are part of a pre-arranged plan and do not necessarily indicate a change in the executive's outlook on the company.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. The use of a 10b5-1 plan provides a structured and transparent framework for these transactions.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar mechanisms for executive compensation and stock transactions.
- The specifics of these plans, such as vesting schedules and exercise prices, vary based on company-specific factors and executive performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the plan should mitigate concerns.
Key Dates
| Date | Description |
|---|---|
| 2021-03-15 | Date stock options exercisable |
| 2024-12-24 | Date of establishment of the 10b5-1 plan |
| 2025-03-15 | Expiration date of stock options |
| 2025-04-17 | Date of stock option exercise and share sales |
| 2025-04-18 | Date of Form 4 filing |
Keywords
United Therapeutics, UTHR, Paul Mahon, Stock Options, Form 4, 10b5-1 Plan, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.